bm-navigation: bm-t1-home-navigation-1
bm-pageheader: bm-t2-aboutus-pageheader


Decades of therapeutic and diagnostic improvements have provided considerable benefit to cancer patients battling their primary tumors.

Unfortunately, those battling relapse and metastasis have not benefited as much from these advancements and they now account for the vast majority of cancer-related deaths. To this day, there are limited treatment options in this setting.

At HiberCell, we are focused on developing novel therapeutics to overcome foundational barriers that prevent patients from living longer, cancer-free lives.

Our Story

HiberCell was launched in 2019 by ARCH Venture Partners and other leading investors in life science. Our team recognized a problem in the cancer treatment and drug development paradigm: while most patients who succumb to cancer do so because of cancer relapse and metastasis, the majority of resources in cancer research were devoted to developing therapies for primary tumors. We set out to shift that paradigm. Building on pioneering tumor dormancy research conducted by the Julio Aguirre-Ghiso Lab at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, HiberCell has grown from a preclinical biotechnology company focused on preventing cancer metastasis and relapse to a multi-asset company dedicated to interrogating and solving the foundational barriers that prevent patients from living longer cancer-free lives.

View Our Team